- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- DCVAC/PCa, Placebo
- Biological
- Lead sponsor
- SOTIO a.s.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 58
- States / cities
- Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2185–2208
of 9,537
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Premature Neonate
- Interventions
- Higher permissive hypercapnia, Lower Permissive Hypercapnia
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 7 Days to 14 Days
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Acute Coronary Syndrome
- Interventions
- Iodofiltic acid I 123
- Drug
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 33 more
- Conditions
- Leukemia
- Interventions
- clofarabine, cytarabine, methotrexate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Downey, California • Long Beach, California + 65 more
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Proton Beam Radiation Therapy
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 128 more
- Conditions
- Fracture of Radius and Ulna
- Interventions
- Cast
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Saxagliptin + Metformin, Placebo + Metformin, Pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 95
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 92 more
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Mail and Live Phone, Interactive Voice Response (IVR), Home-based Computer Kiosk, Traditional Evaluation Instruments
- Behavioral
- Lead sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Irvine, California + 23 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Tesaglitazar, Pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more
- Conditions
- Parkinson Disease
- Interventions
- sumanirole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 984 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 100 more
- Conditions
- Influenza Immunization
- Interventions
- Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 9 Years to 49 Years
- Enrollment
- 1,308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 16 more
- Conditions
- Family Relations, Blight
- Interventions
- Community Health through Engagement and Environmental Renewal (CHEER)
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 915 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma, Metastatic Undifferentiated Round Cell Sarcoma, Metastatic Undifferentiated Sarcoma, Not Otherwise Specified, Round Cell Sarcoma With EWSR1-non-ETS Fusion, Sarcoma With BCOR Genetic Alterations
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Fludeoxyglucose F-18, Ifosfamide, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Regorafenib, Surgical Procedure, Vincristine Sulfate
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Honolulu, Hawaii • Chicago, Illinois + 5 more
- Conditions
- Psoriasis
- Interventions
- BI 730357, Placebo to match BI 730357
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- Not listed
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 12 more
- Conditions
- Asthma
- Interventions
- Albuterol Spiromax, ProAir HFA, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more
- Conditions
- Lymphoma, Non Hodgkin
- Interventions
- Cyclophosphamide, Doxorubicin, Obinutuzumab, Polatuzumab Vedotin, Prednisolone, Prednisone, Rituximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Greeley, Colorado • St Louis, Missouri + 3 more
- Conditions
- Dementia, Psychiatric Disorders Mood, Behavior Disorders
- Interventions
- Delayed results of pharmacogenomic results
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Breast Adenocarcinoma
- Interventions
- Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 840
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more
- Conditions
- HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
- Interventions
- Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 730 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- HER2 Positive Breast Cancers
- Interventions
- Tucatinib (ONT-380), T-DM1
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Kansas City, Kansas + 4 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
- Conditions
- Diabetes Mellitus, Kidney Transplant; Complications
- Interventions
- Free style libre-2
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama